Hanmi does not infringe AstraZeneca's Nexium: U.S.court

The drug company AstraZeneca PLC lost a bid on Thursday to defend its widely used heartburn drug Nexium when an appeals court ruled that a new drug from Hanmi Pharmaceuticals did not infringe on Nexium patents. The U.S. Court of Appeals for the Federal Circuit upheld a lower court's ruling that Hanmi did not infringe on AstraZeneca's patent since the South Korean company uses different salts in making its products. "AstraZeneca respectfully disagrees with the court's decision. The Federal Circuit issued an injunction against the Hanmi drug in August, but lifted it in September, AstraZeneca said earlier this week.



via Health News Headlines - Yahoo News http://news.yahoo.com/hanmi-does-not-infringe-astrazeneca-39-nexium-u-204731548--finance.html